Paul Leger

1.1k total citations
31 papers, 738 citations indexed

About

Paul Leger is a scholar working on Infectious Diseases, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Paul Leger has authored 31 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Paul Leger's work include HIV/AIDS Research and Interventions (12 papers), HIV/AIDS drug development and treatment (11 papers) and HIV Research and Treatment (7 papers). Paul Leger is often cited by papers focused on HIV/AIDS Research and Interventions (12 papers), HIV/AIDS drug development and treatment (11 papers) and HIV Research and Treatment (7 papers). Paul Leger collaborates with scholars based in United States, Haiti and Switzerland. Paul Leger's co-authors include Jean W. Pape, Daniel W. Fitzgerald, Patrice Sévère, Macarthur Charles, Roy M. Gulick, Warren D. Johnson, David W. Haas, Peter F. Wright, Francine Noël and Stefan Kénel-Pierre and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Paul Leger

27 papers receiving 710 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Leger United States 15 517 278 181 111 82 31 738
Laura Farrelly United Kingdom 13 304 0.6× 96 0.3× 217 1.2× 192 1.7× 42 0.5× 49 874
Fabrizio Soscia Italy 10 524 1.0× 335 1.2× 217 1.2× 56 0.5× 119 1.5× 17 784
Xien Gui China 13 361 0.7× 116 0.4× 235 1.3× 58 0.5× 32 0.4× 46 618
Christa Dreezen Belgium 12 354 0.7× 191 0.7× 134 0.7× 351 3.2× 133 1.6× 31 1.0k
Claire Raskino United States 12 307 0.6× 365 1.3× 103 0.6× 31 0.3× 75 0.9× 19 713
George Perez United States 15 413 0.8× 169 0.6× 353 2.0× 36 0.3× 143 1.7× 36 785
James Sampson United States 9 234 0.5× 158 0.6× 144 0.8× 54 0.5× 101 1.2× 12 500
Filip Josephson Sweden 15 581 1.1× 248 0.9× 906 5.0× 328 3.0× 86 1.0× 30 1.5k
John F. Sullivan United States 10 502 1.0× 574 2.1× 154 0.9× 51 0.5× 75 0.9× 14 955
Christopher M Ndugwa Uganda 16 291 0.6× 120 0.4× 214 1.2× 180 1.6× 130 1.6× 32 841

Countries citing papers authored by Paul Leger

Since Specialization
Citations

This map shows the geographic impact of Paul Leger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Leger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Leger more than expected).

Fields of papers citing papers by Paul Leger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Leger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Leger. The network helps show where Paul Leger may publish in the future.

Co-authorship network of co-authors of Paul Leger

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Leger. A scholar is included among the top collaborators of Paul Leger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Leger. Paul Leger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zwart, Alan, Dinesh Kumar, Paul Leger, et al.. (2024). Impact of neoadjuvant relugolix on patient-reported sexual function and bother. Frontiers in Oncology. 14. 1377103–1377103. 1 indexed citations
3.
Zwart, Alan, Deepak Kumar, Paul Leger, et al.. (2024). The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue. Frontiers in Oncology. 14. 1412786–1412786.
4.
5.
Xiao, Jerry, Alan Zwart, Thomas Yung, et al.. (2023). Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. Frontiers in Oncology. 13. 1289249–1289249. 1 indexed citations
6.
7.
Wang, Daniel, Zeynep Eroglu, Alpaslan Özgün, et al.. (2017). Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma. Cancer Immunology Research. 5(5). 357–362. 35 indexed citations
8.
Rothschild, Sacha I., et al.. (2017). Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC. Annals of Oncology. 28. ii33–ii33. 8 indexed citations
9.
Leger, Paul, Emily Castellanos, Rathi N. Pillai, & Leora Horn. (2017). P2.03a-049 Response to Salvage Chemotherapy Following Exposure to PD-1 Inhibitors in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S918–S919. 1 indexed citations
10.
Leger, Paul, Andrew H. Limper, & Fabien Maldonado. (2017). Pulmonary Toxicities from Conventional Chemotherapy. Clinics in Chest Medicine. 38(2). 209–222. 28 indexed citations
11.
Leger, Paul, Sanika Chirwa, Megan Turner, et al.. (2016). Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race. Pharmacogenetics and Genomics. 26(10). 473–480. 17 indexed citations
12.
Sinxadi, Phumla, Paul Leger, Helen McIlleron, et al.. (2015). Pharmacogenetics of plasma efavirenz exposure in HIV‐infected adults and children in South Africa. British Journal of Clinical Pharmacology. 80(1). 146–156. 60 indexed citations
13.
Leger, Paul, Daniel H. Johnson, Gregory K. Robbins, et al.. (2014). Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. Journal of NeuroVirology. 20(3). 304–308. 13 indexed citations
14.
Bertrand, Julie, Monidarin Chou, Danielle Richardson, et al.. (2012). Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenetics and Genomics. 22(12). 868–876. 26 indexed citations
15.
César, Carina, Bryan E. Shepherd, Alejandro Krolewiecki, et al.. (2010). Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America. PLoS ONE. 5(6). e10490–e10490. 47 indexed citations
16.
Koenig, Serena P., Cynthia Riviere, Paul Leger, et al.. (2009). High Mortality among Patients with AIDS Who Received a Diagnosis of Tuberculosis in the First 3 Months of Antiretroviral Therapy. Clinical Infectious Diseases. 48(6). 829–831. 45 indexed citations
17.
Leger, Paul, Rebecca Dillingham, Angela D. M. Kashuba, et al.. (2009). CYP2B6Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port‐au‐Prince, Haiti. The Journal of Infectious Diseases. 200(6). 955–964. 34 indexed citations
18.
Leger, Paul, Macarthur Charles, Patrice Sévère, et al.. (2009). 5-Year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti. New England Journal of Medicine. 361(8). 828–829. 25 indexed citations
19.
Koenig, Serena P., Cynthia Riviere, Paul Leger, et al.. (2008). The cost of antiretroviral therapy in Haiti. Cost Effectiveness and Resource Allocation. 6(1). 3–3. 24 indexed citations
20.
Sévère, Patrice, Paul Leger, Macarthur Charles, et al.. (2005). Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti. New England Journal of Medicine. 353(22). 2325–2334. 234 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Farrelly Breakdown of academic impact, for papers by Fabrizio Soscia Breakdown of academic impact, for papers by Xien Gui Breakdown of academic impact, for papers by Christa Dreezen Breakdown of academic impact, for papers by Claire Raskino Breakdown of academic impact, for papers by George Perez Breakdown of academic impact, for papers by James Sampson Breakdown of academic impact, for papers by Filip Josephson Breakdown of academic impact, for papers by John F. Sullivan Breakdown of academic impact, for papers by Christopher M Ndugwa
Rankless by CCL
2026